Fernando N. Araujo, Chief Financial Officer and Treasurer of TransMedics Group, Inc., filed a Form 4 on October 30, 2026, disclosing the acquisition of 22,969 restricted stock units and a stock option covering 34,419 shares of common stock, both dated October 28, 2026.

Key Highlights

  • RSU Grant: Araujo acquired 22,969 restricted stock units on October 28, 2026, at a price of $0, each representing a contingent right to receive one share of TransMedics Group common stock.
  • Stock Option Grant: A stock option to purchase 34,419 shares of common stock was granted at an exercise price of $66.9, also on October 28, 2026, expiring October 28, 2036.
  • Vesting Schedule: The option vests as to 25% of the underlying shares on September 21, 2027, with the remaining shares vesting in equal monthly installments over three years thereafter, subject to continued service.
  • Resulting Ownership: Following the transactions, Araujo directly holds 22,969 shares of common stock and 34,419 derivative securities beneficially owned.
  • Reporting Person Role: Araujo is identified in the filing as Chief Financial Officer and Treasurer of TransMedics Group, Inc., listed on NASDAQ:TMDX.

Araujo's October 2026 Equity Awards at TransMedics Group

According to the Form 4 filed with the SEC on October 30, 2026, Fernando N. Araujo, Chief Financial Officer and Treasurer of TransMedics Group, Inc. (NASDAQ:TMDX), reported two equity award transactions dated October 28, 2026. The filing was signed by Matthew S. Forsyth as Attorney-in-Fact on Araujo's behalf.

The first transaction involved the acquisition of 22,969 restricted stock units classified under transaction code "A" (acquired) at a price of $0. The filing states that each RSU "represents a contingent right to receive one share of the Issuer's common stock." Following this grant, Araujo directly beneficially owns 22,969 shares of common stock as reported in Table I of the filing.

The second transaction, reported in Table II, was the acquisition of a stock option providing the right to purchase 34,419 shares of TransMedics Group common stock at an exercise price of $66.9 per share. The option has an expiration date of October 28, 2036. According to the filing, the option vests as to 25% of the underlying shares on September 21, 2027, with the remaining shares vesting "in equal monthly installments over three years thereafter, subject to continued service." The price of the derivative security at grant is listed as $0, and Araujo directly holds 34,419 derivative securities following the transaction.

What Was Disclosed

TransMedics Group CFO and Treasurer Fernando N. Araujo reported receiving 22,969 RSUs and a stock option for 34,419 shares at $66.9 per share, both granted October 28, 2026, with the option expiring October 28, 2036.